Tardive Dyskinesia: Switching Agents vs. Adding a VMAT2 Inhibitor
New involuntary facial movements after years of stable antipsychotic treatment used to mean switching and hoping. A newer class of drug designed for exactly this now makes that traditional first response genuinely optional.
L.M., a 52-year-old woman, raised two children largely on her own through the most unstable years of her illness, something her now-adult daughter brings up with real emotion when describing how far her mother has come. L.M. has been stable on risperidone for nine years following a long and difficult early illness course, and her family describes her current baseline — independent living, a part-time job at a library, close relationships with her adult children — as the best sustained period of her adult life.
Over the past four months, her daughter noticed new involuntary lip-smacking and tongue movements, confirmed on exam as tardive dyskinesia with a documented AIMS score in the mild-to-moderate range, clearly related to her long-term risperidone exposure. L.M. herself says she hadn't noticed the movements at all until her daughter pointed them out, and both are now anxious about what any change to her medication regimen could mean for the stability they've worked so hard to reach.
The traditional approach to a new TD diagnosis is switching the causative antipsychotic, historically to one thought to carry a lower TD liability, with no guarantee the existing psychiatric stability survives the change. VMAT2 inhibitors, approved specifically for tardive dyskinesia, offer a genuinely different path: adding a targeted agent to treat the movement disorder directly while leaving an antipsychotic regimen that has worked for nine years untouched. Both options are real and defensible; the difference is whether the team treats a nine-year stable regimen as too valuable to risk switching, or treats a confirmed drug-induced movement disorder as reason enough to remove the causative agent regardless of a good alternative existing.
Switch the antipsychotic, or add a VMAT2 inhibitor
I'd add a VMAT2 inhibitor and leave risperidone alone. Nine years of stability this good is not something I'm willing to gamble on a switch when we now have a treatment designed to address the movement disorder directly without touching the regimen that got her here.
I understand not wanting to gamble on nine years of stability — that's a real thing to protect, and I'm not dismissing it. But I want to name plainly that "leave the regimen untouched" isn't quite what adding a VMAT2 inhibitor does. It's a new, ongoing medication with its own tolerability profile to monitor, not a one-time fix — sedation is common, and at least one large trial of this drug class reported psychiatric symptom worsening in a subset of patients.
You called it a treatment that works "without touching the regimen that got her here" — but adding a second permanent medication to avoid touching the first one is still a real change to what she's taking every day, with its own real risk, not a neutral option next to a risky one. The traditional argument for removing the causative agent once a safe alternative exists doesn't stop being valid just because a targeted add-on now exists too.
Both of those risks are real, but I don't think they're evenly weighted for her specifically. KINECT 3, the pivotal placebo-controlled trial of this drug class, enrolled patients much like her — most already stable on an ongoing antipsychotic — and found a real, statistically significant reduction in AIMS score at six weeks, with psychiatric status reported stable in the large majority of participants. Her AIMS score is mild-to-moderate, not severe, which is exactly the range that trial's benefit was demonstrated in. That's what tips it for me toward the VMAT2 inhibitor: not that the switching option is wrong in principle, but that the evidence for this specific choice, at her specific severity, is genuinely strong. A more severe presentation, or a patient who couldn't tolerate the added agent, might tip this the other way.
Agreed: continue risperidone unchanged, start a VMAT2 inhibitor for the tardive dyskinesia, and repeat AIMS assessment at three months to track movement response.
L.M. and her daughter were told directly that a switch remains available if the VMAT2 inhibitor doesn't adequately control the movements, so today's choice isn't presented as the only option, only as the one that best protects what's currently working.